Protagonist Therapeutics (PTGX) PT Raised to $165 at Citizens as Icotyde Revenue Ramps

July 17, 2026 5:06 AM

Citizens analyst Jonathan Wolleben raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $165.00 (from $137.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found